


Catalogue Number	Product	Order number / Unit
9772	<p>DOTA-TATE acetate (GMP)</p> <p>Precursor for radiolabelled DOTA-[Tyr³]octreotate</p> <p>Manufactured according to GMP requirements for APIs for use in clinical trials (ICH Q7 chapter 19)</p> <p>Sold under license for patent EP1872800</p> <p>Molar Mass: 1435.63</p> <p>C₆₅H₉₀N₁₄O₁₉S₂</p> <p>[177943-89-4]</p> <p>Colourless to off-white solid packaged in plastic vials</p> <p>Purity: > 97 % (9772.0001) > 95 % (9772.0000.05, 9772.0000.10, 9772.0000.25 and 9772.0000.40)</p> <p>Certificates: CoA with ESI-MS (identity); HPLC (purity); GC (residual solvents, acetate content, water content); microbiology test</p> <p>Chemical Name: DOTA-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH, cyclic disulfide DOTA = N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]- Supplied as acetate salt</p> <p>Synonymes: DOTA-[Tyr³]-Octreotate, DOTA-[Tyr³, Thr⁸]-Octreotide</p> <p>Literature: De Jong M. et al. Combination Radionuclide Therapy Using ¹⁷⁷Lu- and ⁹⁰Y-Labeled Somatostatin Analogs. J. Nucl. Med., 2005, 46,13S Valkema R. et al. Long-Term Follow-Up of Renal Function After Peptide Receptor Radiation Therapy with ⁹⁰Y-DOTA⁰,Tyr³-Octreotide and ¹⁷⁷Lu-DOTA⁰,Tyr³-Octreotate. J. Nucl. Med. 2005, 46, 8</p>	<p>9772.0000.05: 50 µg per vial 9772.0000.10: 100 µg per vial 9772.0000.25: 250 µg per vial 9772.0000.40: 400 µg per vial 9772.0001: 1 mg per vial Please inquire for customized filling and bulk quantities.</p> 

date of product catalogue issue: 10 May 2017